ClinicalTrials.Veeva

Menu

Drug Discovery for Parkinson's with Mutations in the GBA Gene

N

New York Stem Cell Foundation Research Institute

Status

Enrolling

Conditions

Healthy
Gaucher Disease
Parkinson Disease
GBA Gene Mutation

Treatments

Other: Biological Sample Collection

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate Parkinson's disease research and drug development by using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and/or store the samples for future use.

Through this research, researchers hope to identify future treatments or even cures for Parkinson's disease.

Full description

Researchers at the New York Stem Cell Foundation (NYSCF) Research Institute study diverse diseases, conditions, and traits by creating stem cells from biological samples. These "pluripotent" stem cells can become any cell in the human body, including cells that may be difficult, invasive, or impossible to obtain directly.

Additionally, researchers perform genetic testing to learn more about DNA, a material in most cells that contains instructions for the body's development and functions (such as traits like eye color and risk of certain diseases). A piece of DNA that determines the specific role of a cell is called a "gene." If the instructions in a gene are abnormal, this can lead to disease.

Participation in the study involves: (1) completion of health questionnaires, (2) providing a skin and/or blood sample from which stem cells may be created, (3) collection of a saliva sample for genetic analysis, and (4) possible future follow-up to provide additional information or learn about other research studies.

This study is not a clinical trial.

Enrollment

60 estimated patients

Sex

All

Ages

18 to 100 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Age 18 years or older.
  • Diagnosis of Parkinson's disease, Gaucher disease, or healthy control.
  • Must provide written informed consent unless physical limitations preclude signing.

Exclusion criteria

  • For skin samples collected specifically for this study: history of keloid formation, coagulation disorder, allergy to the anesthetic, or anticoagulation use that precludes sample collection.
  • For blood samples collected specifically for this study: coagulation disorder or other medical condition(s) that increases the risks associated with blood collection.
  • For all prospective sample collections: Subjects who refuse to adhere to NYSCF's and/or a collection site's safety protocols will be excluded. Subjects with an AIDS diagnosis and CD4 count of less than 200 cells per microliter (mcL) of blood will be excluded due to increased risk of infection.

Trial design

60 participants in 3 patient groups

Parkinson's Disease
Description:
Subjects in this group will have a diagnosis of Parkinson's disease with or without a known GBA gene mutation.
Treatment:
Other: Biological Sample Collection
Gaucher Disease
Description:
Subjects in this group with have a diagnosis of Gaucher disease with or without a known GBA gene mutation.
Treatment:
Other: Biological Sample Collection
Healthy Control
Description:
Subjects in this group will serve as healthy controls.
Treatment:
Other: Biological Sample Collection

Trial contacts and locations

1

Loading...

Central trial contact

Clinical Research Office

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems